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Major hemoptysis a potentially life-threatening condition in pulmonology and can originate
from both identifiable and unidentifiable sites. Identifiable bleeding sites can be controlled
locally by iced saline, vasopressors, laser, electrocautery and balloon tamponade. Bleeding
from an unidentifiable source, on the other hand, is much more difficult to control as the
bleeding site is not accessible by the bronchoscope. Tranexamic acid (TA), a synthetic anti-
fibrinolytic agent, is approved for treatment or prophylaxis of bleeding episodes in hemophilia
or following major operative procedures via intravenous or oral routes. Its efficacy in control-
ling bleeding from mucosal tissue led us to apply it to patients with pulmonary bleeding. Six
patients with significant hemoptysis, two who bled during bronchoscopy biopsy and four with
spontaneous bleeding (lung cancer, diffuse alveolar hemorrhage, idiopathic pulmonary
bleeding, metastatic thyroid carcinoma) were treated with TA. For the two who bled during
bronchoscopy, we used a bolus of 500 mg/5 mL through the bronchoscope working channel,
while the latter four received aerosolized TA 500 mg/5 ml 3e4 times a day. In all cases, the
bleeding stopped with the first dose of TA, and the treatment was well tolerated without
adverse events. While limited due to the small number of patients, these data show that TA
administered either as a bolus through the bronchoscope or via inhalation seems to be effec-
tive in controlling severe hemoptysis from both identifiable and unidentifiable bleeding sites.
Further clinical studies are needed to evaluate the use of the TA in this set-up.
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Hemoptysis, a frequent symptom in pulmonary diseases,
refers to identifiable bleeding from major airways or to
unidentifiable bleeding from the lung parenchyma. Identi-
fiable bleeding originates mostly from endobronchial.
Pulmonary hemorrhage 1197lesions, either spontaneously or following diagnostic or
therapeutic procedures. Unidentifiable bleeding originates
mostly from vascular injury to more distal vessels and tends
to be spontaneous. Regardless of the etiology, pulmonary
bleeding can be severe and life-threatening, requiring
prompt intervention to stop the bleeding. Identifiable
bleeding sites are managed with the instillation of cold
water and/or vasopressors and/or balloon tamponade
through the bronchoscope. In selected, equipped medical
centers, laser coagulation or electrocautery and bronchial
artery embolism (if an abnormal vessel can be recognized)
are performed.1e7
The therapeutic options for unidentifiable bleeding, on
the other hand, for example, diffuse alveolar hemorrhage,
are limited and include correction of coagulation defects (if
present) along with supportive treatment.8e10 There is no
doubt that further treatment modalities for pulmonary
bleeding are needed.
Tranexamic acid, a synthetic anti-fibrinolytic agent, has
been approved for many years for the treatment or
prophylaxis of bleeding episodes in patients with bleeding
disorders or following major operative procedures via
intravenous or oral routes. Its effectiveness in controlling
local bleeding from mucosal tissue in the nose, colon,
rectum and mouth led us to evaluate its activity in
pulmonary bleeding.11e13 This report summarizes our
preliminary experience with tranexamic acid to treat
pulmonary bleeding of varying etiologies.
Methods
Following are the results of the experimental treatment of
patients with severe pulmonary bleeding not responding to
conventional medical therapy. Usual measures included
steroids and antibacterial agents in cases of diffuse alveolar
hemorrhage and topical application of iced saline with
adrenaline in cases of identifiable bleeding during bron-
choscopy. Six patients hospitalized in Rambam Health Care
Campus, a 900-bed tertiary care-center, university-affili-
ated hospital, who experienced severe pulmonary hemor-
rhage unresponsive to conventional treatment during their
hospital stay, received experimental treatment with TA.
The present case series describes 6 patients in whom
permission to administrate TXA either by inhalation or by
topical application was given by the local ethical
committee as an off-label treatment. A protocol that was
approved by the local ethical committee ensured that all
patients with uncontrolled bleeding encountered during
clinical practice would be eligible to this compassionate
treatment without informed consent.
Patients with uncontrolled pulmonary hemorrhage
either from identifiable or unidentifiable sources were
included. For unidentifiable bleeding episodes, we used
inhaled tranexamic acid 500 mg/5 ml 3e4 times a day
(Hexakapron, TEVA Group, Tel-Aviv, Israel), and for iden-
tifiable bleeding episodes we used boluses of tranexamic
acid administered through the working channel of the
flexible bronchoscope. Each ampoule of 5 ml contained
500 mg of tranexamic acid dissolved in water for injection,
sodium hydroxide and hydrochloric acid (for pH adjust-
ment). A quantitative and qualitative (verbal) evaluation of
the symptoms was made, such as general clinicalevaluation, chest X-ray, and blood tests. Data on the
patients are presented in Table 1. Clinical follow-up was
until discharge or death and as of writing of this manuscript
no patient dropped from follow-up (maximum of follow-up
2 years).
Patient no. 1
A 67-year-old male was admitted with hemoptysis. Renal
cell carcinoma has been diagnosed three years earlier for
which he underwent radical nephrectomy followed by
chemotherapy and immunotherapy. Right upper lobe
metastasis diagnosed two years earlier was treated by
external radiotherapy. Chest CT revealed a large endo-
bronchial mass in the right upper lobe bronchus. Fiberoptic
bronchoscopy confirmed bleeding from this lesion. An
attempt to perform bronchoscopic electrocautery resulted
in massive bleeding (approximately 750 ml of blood) that
did not respond to a bolus of iced saline and instillation of
epinephrine through the bronchoscope. At that time,
a bolus of 500 mg (vial) of TA was instilled through the
bronchoscope working channel with immediate cessation of
the bleeding within 30e60 s. The patient remained stable
for the next few days, did not bleed, and was discharged.
Patient no. 2
A 43-year-old male presented with recurrent episodes of
significant hemoptysis of 3 weeks’ duration followed by
a reduction of 5 g% in hemoglobin. He had suffered from
multiple, bilateral, inoperable, pulmonary metastases of
medullary thyroid carcinoma over the last 10 years for
which he underwent surgery, chemotherapy and radiation
therapy. He also suffered from right vocal cord and right
diaphragmatic paralysis, along with hypoxemia and
pulmonary hypertension treated at home with nasal posi-
tive pressure ventilation oxygen and Endothelin-1 antago-
nists. A chest CT showed bilateral masses compressing the
main bronchi and bronchoscopy revealed narrowed bronchi
to the left and the right sides along with irritated mucosa
and signs of blood coming from distal unidentifiable sites on
both sides. Aerosolized TA (500 mg/5 ml) four times a day
resulted in immediate and complete cessation of the blood.
The time frame elapsing from application of TXA to cessa-
tion of overt bleeding was 15e20 min. An attempt to stop
the therapy after 72 h resulted in a new episode of
hemoptysis which also responded well to this therapy. The
patient continued to inhale a half-vial e 2.5 ml (250 mg) e
of TA two to three times a day as preventive therapy.
Overall, he received this treatment for three months
without side effects. Later, the frequency of the inhalation
was gradually reduced to once a day and finally could be
stopped.
Patient no. 3
A 49-year-old female with myelofibrosis since 1998 under-
went splenectomy in 2005. In 2006 her disease transformed
into acute myeloid leukemia and she eventually underwent
haploidentical bone-marrow transplantation (BMT) with
complete remission of the leukemia. Six months after the
BMT she developed idiopathic thrombocytopenic purpura
Table 1 Clinical characteristics.
Pt. No. 1 2 3 4 5 6
Age/gender 67/M 43/M 49/F 52/M 57/M 59/M
Bleeding cause Spontaneous Tumor
(spontaneous)
Spontaneous Spontaneous Tumor
(bronchoscopic biopsy)
Spontaneous
Co-morbidity Kidney tumor Pulmonary
metastatsis
of thyroid ca
ITP s/p BMT for
AML
Lung ca Lung ca None
Mode of
treatment
Instillation
through the
bronchoscope
Inhalation Inhalation Inhalation Instillation through
the bronchoscope
Inhalation
Dose 500 mg/5 ml 500e250 mg
2e3 times/day
500 mg qid 500 mg qid 500 mg/5 ml 500 mg qid
Length of
treatment
Single dose 3 months One week 3 days Single dose 2 days
Notes: MZmale; FZ female; CaZ carcinoma; s/p BMTZ status post-bone-marrow transplantation; ITPZ idiopathic thrombocyto-
penic purpura; and AMLZ acute myeloid leukemia.
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corticosteroids with no response. A month later she was
admitted to hospital with hemoptysis, shortness of breath,
hypoxia, new diffuse bilateral diffuse alveolar infiltrates,
and a drop of 2 g% in hemoglobin values with a platelet
count of 3000/mL, consistent in this set-up with the diag-
nosis of diffuse alveolar hemorrhage (DAH). BAL findings
were consistent with the diagnosis of DAH and she was
treated with immunoglobulin, high-dose steroids, platelet
transfusion and CPAP ventilation enriched with 100%
oxygen. One day after admission, the platelet counts were
3000/ml, hemoglobin had decreased by a further 1 g% and
her respiratory status continued to deteriorate. At this
point we put her on inhalations of TA (500 mg) every 6 h.
The hemoptysis stopped within a 2e3-h and her respiratory
status stabilized. A few days later it had improved signifi-
cantly along with disappearance of the pulmonary infil-
trates. Two days later she was able to walk along the
corridor without oxygen. TA was stopped after one week of
therapy without recurrence of the bleeding.
Patient no. 4
A 52-year-old male with a history of heavy smoking pre-
sented with shortness of breath, fever and purulent sputum
of a few days’ duration. He was treated with broad spec-
trum antibiotics and oxygen mask. In 1999, diffuse mixed
small cleaved and large cell lymphoma had been diagnosed.
Over the years, he experienced multiple relapses managed
with several lines of chemotherapy, including autologus
BMT. On the 10th day of the current hospitalization, he
developed significant hemoptysis of 500 ml. CBC disclosed
a thrombocyte count of 70,000/mm3 and normal coagula-
tion studies. Chest CT disclosed a left lower lobe cavitary
lesion along with extensive consolidation. Due to the poor
respiratory status, BAL was delayed and the patient was put
on inhalations of TA 500 mg every 6 h for three days, again
with rapid resolution of the hemoptysis. Bronchoscopic
biopsy performed three days later demonstrated poorly
differentiated squamous cell carcinoma. The patient
eventually died during this hospital stay from sepsis without
active bleeding.Patient no. 5
A 57-year-old male was admitted to the emergency room
with fever, productive cough and dyspnea. His past medical
history was unremarkable except for smoking of 60 pack-
years until 12 years ago. CT of the chest revealed a 2.5-cm
sized mass in the right upper lobe. He was put immediately
on broad spectrum antibiotics with resolution of the fever.
Bronchoscopy performed one day after admission revealed
a normal bronchial tree. During transbronchial biopsy,
massive bleeding (600 ml) occurred with a reduction of 2 g%
in hemoglobin. Two doses (500 mg/5 ml each) of TA were
instilled through the bronchoscope to the affected
segment, resulting in the immediate and complete cessa-
tion of the bleeding. The biopsy sample showed non-small
cell lung carcinoma. The patient was discharged and is
scheduled for resection of the lung cancer.
Patient no. 6
A 59-year-old previously healthy man with retinal detach-
ment underwent elective left-eye vitrectomy. Following
uneventful surgery under general anesthesia he was extu-
bated. A few minutes later, a bloody cough developed. On
physical examination he had 30 breaths per minute, pulse
of 130/min and O2 saturation of 85e87% while breathing
room air. Urgent chest radiograph followed by chest CT
scan confirmed the presence of diffuse, confluent, and
bilateral alveolar opacities. No endobronchial mass was
observed on bronchoscopy. Subsequent laboratory studies
showed a drop in hemoglobin level (12 g%) compared to
baseline values (15 g%). Platelet count, coagulation studies
and blood chemical values were within normal limits.
Oxygen (15 l/min) was given via non-re-breathing mask,
resulting in oxygen saturation of 93%. He was put on inhaled
TA (500 mg qid) for 48 h with almost instantly stopping of
the hemoptysis. Follow-up fiberoptic bronchoscopy per-
formed 48 h later revealed signs of old inactive bleeding in
the bronchus to the posterior segment of the left lower lobe
and no endobronchial lesion. Abdominal CT revealed an
irregular mass in the left kidney, later diagnosed as renal
cell carcinoma.
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This report describes the effectiveness of administrating TA
to six patients with pulmonary hemorrhage of varying
etiologies. Two patients with significant bleeding from
malignant tumors during bronchoscopy (one during a trans-
bronchial biopsy) responded immediately to a bolus of TA
500 mg/5 ml injected directly through the bronchoscope
working channel to the bleeding site in the patient with the
identifiable tumor and to the affected segment in the
patient who bled during the transbronchial biopsy. The
remaining four patients with spontaneous bleeding of
varying etiologies e endobronchial tumor, unidentifiable
lung metastasis, DAH and idiopathic pulmonary bleeding e
were managed with inhalations of TA (250e500 mg) up to
four times a day and responded immediately. Only one
patient with non-resectable lung metastasis required three
months of therapy.
Tranexamic acid, a synthetic derivative of the amino
acid lysine, possesses anti-fibrinolytic activity because it
binds to plasminogen, blocks its binding to fibrin, and
subsequent activation to plasmin.11 It has been approved
for more than 30 years for treatment and/or prophylaxis of
bleeding episodes in patients with hemophilia, ITP, and
following major operative procedures via intravenous or
oral routes. Its effectiveness in controlling local bleeding
from mucosal tissue in the mouth, gingival, nose, vagina,
and rectum led us to evaluate its activity in pulmonary
bleeding.
The rationale for administrating inhaled TA to pulmonary
bleeding was to enhance the activity of depleted anti-
fibrinolytic factors in ongoing bleeding sites along the
bronchial tree.14 The pulmonary distribution of oral and IV
TA is not known. Sindet-Pedersen’s observation of much
higher concentrations of TA in saliva after a mouth rinse
with 10 mL of a 5% aqueous TA solution than after oral
administration of 1 g of the drug, suggests superior effec-
tiveness of local administration of the drug rather than
systemic treatment. This could translate into better inhi-
bition of fibrinolysis that lasts for many hours with minor
systemic absorption.15 Inhaled TA can also theoretically
decrease the risk of thrombosis associated with systemic
absorption.
The patients who bled during bronchoscopic biopsy
required a single session of therapy, during which a few
boluses of TA were injected directly to the bleeding site,
according to the severity and the duration of the bleeding.
Although patients with unidentifiable bleeding responded
to the first inhalations, this therapy was administered for
few more days (1e7 days). The exact length of therapy
should be clarified better. Although only a small amount of
inhaled TA reached the bleeding site, it was enough to
control the bleeding. All but one patient who died during
the hospital stay from a cause unrelated to the bleeding
episode were discharged from hospital. The TA treatment
was well tolerated without side effects, even in the patient
who received it for three months.
The prevalence of hemoptysis (mostly identifiable) in
patients with primary or secondary lung cancer varies from
24 to 70% with a mortality rate of 10e38%, depending on
the etiology and the magnitude of the bleeding.16,17Bronchoscopy-induced bleeding that requires special
management occurs in 1.8e5% of patients, mostly in the
set-up of bronchial or transbronchial biopsy procedures and
during laser or electrocautery treatment of tracheobron-
chial tumors. While most bleeding episodes are self-
limited, some can be fatal.1,2,4
The management of major hemoptysis includes placing
the patient with a bleeding lung in the dependent position,
if needed to maintain airway patency, with selective intu-
bation of the non-bleeding lung. Identifiable bleeding sites
are managed by instillation of ice-cold saline or with the
administration of vasopressors such as epinephrine
(1:10,000) through the working channel of the broncho-
scope. Of note, about 50% of epinephrine that is systemi-
cally absorbed is liable to produce side effects such as
tachy-arrhythmias and hypertension. Other forms of inter-
vention to control identifiable bleeding include balloon
tamponade, laser and/or electrocautery, all of which
depend on the availability of trained staff in well-equipped
medical centers. A bronchial artery embolism (BAE) applies
mainly for local bleeding when an abnormal vessel is
documented in medical centers with a stand-by angio-
graphic service. The last resort for significant bleeding is
a surgical procedure.5e7,16,17
The management of bleeding from an unidentifiable
source, on the other hand, is more complicated. For local
bleeding from an unidentifiable source, some of the treat-
ments mentioned earlier are applied to the affected
bronchus, although with smaller success rates compared to
identifiable bleeding. Diffuse alveolar bleeding, either
idiopathic or in association with hematological disorders
such as BMT, is a devastating entity with a mortality rate of
70e90% on current therapeutic regimens.9,18,19 The exact
cause of DAH is unknown but it is considered to represent
small vessels abnormality.20,21 The effectiveness of TA in
DAH is encouraging especially in the face of the high
mortality rates of this entity on current therapeutic
strategies.
Oral and IV TA have been used adjunct to BAE to control
hemoptysis in CF patients. Wong has reported successful
management of recurrent minor hemoptysis with oral TA for
four years with no apparent toxicity in a patient with
collateral vessels after failure of BAE.22 Chang presented
a 6-year-old boy who was successfully treated with TA for
five months for hemoptysis that eventually required
lobectomy, despite therapy with TA.23 Graf reported the
effective use of TA in a patient with angiographic evidence
of significant bronchial artery to spinal artery anastomoses
despite multiple BAE procedures. Attempts to withdraw the
TA resulted in recurrence of the bleeding.24
Tranexamic acid mouthwashes enhance hemostasis after
minor oral surgery in warfarinized patients. This approach
permits oral surgical procedures without interruption of
anticoagulant therapy.25 In a randomized, double-blind,
placebo-controlled trial, administration of TA mouthwash
reduced the rate of postoperative bleeding compared with
placebo in 93 anticoagulated patients undergoing dental
surgery.26 Local TA therapy (mouth rinse of 10 ml of a 5%
solution for 2 min, four times daily) was superior to
systemic therapy in controlling spontaneous gingival
bleeding or bleeding following subgingival scaling in
hemophilia.27
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the pleural cavity were successfully treated with oral TA 4 g
in four doses in addition to TA 5 g intrapleurally twice
daily.28 TA administered directly into the pericardial cavity
in patients undergoing coronary bypass operations has been
reported to decrease postoperative bleeding.29
These data show that the local application of TA is highly
effective in controlling bleeding of different causes. No
significant adverse effects have been noted during the local
use of tranexamic acid.
The data presented show that TA is an additional effec-
tive method of treating patients with significant respiratory
bleeding, mostly because this cheap and safe medication is
easy to administer and does not require a special set-up. It
can be used for identifiable bleeding sites in a bolus directly
through the bronchoscope working channel, thus contrib-
uting to the management of bleeding in hospitals not
equipped with laser or electrocautery. In equipped medical
centers it can be administered to patients with identifiable
bleeding through a rigid bronchoscope. More importantly,
the ability to administer it for both identifiable bleeding
from an unidentifiable source through inhalation suggests
that it could be considered for pulmonary bleeding in the
emergency room and/or in internal medicine departments,
instead of or until bronchoscopic procedures are available.
While limited due to the small number of patients, these
data show that TA application administered either as a bolus
through the bronchoscope or via the inhalation seems to be
effective in controlling severe hemoptysis from both iden-
tifiable and unidentifiable bleeding sites. Further prospec-
tive randomized clinical studies are needed to evaluate the
use of the TA in this set-up.
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